RGENIX to Present at H.C. Wainwright 22nd Annual Global Investment Conference
New York, NY – September 02, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it has been selected to present at the H.C. Wainwright 22nd Annual Global Investment
RGENIX to Present at Multiple Virtual Healthcare Investor Conferences in August
New York, NY – Aug 05, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it has been selected to present at multiple virtual healthcare investor conferences taking place during the month of August. These conferences include: LifeSci Partners Summer Symposium August 5, 2020
RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting
New York, NY - June 22, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-104, RGENIX’s lead therapy in development. RGENIX’s abstract, “Correlative
RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting
New York, NY - June 22, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-019, RGENIX’s pre-clinical antibody program in development. RGENIX’s abstract,
RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial
Data from Phase 1 Trial of RGX-202 Presented at 2020 ASCO Virtual Scientific Program New York, NY - May 29, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is